Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;105(12):e4393-e4406.
doi: 10.1210/clinem/dgaa348.

The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis

Mustafa Tosur  1 , Mario A Cleves  2 , Jay M Sosenko  3 , Ingrid Libman  4 , David A Baidal  3 , Ashok Balasubramanyam  5 , Maria J Redondo  1 ; Type 1 Diabetes TrialNet Study Group
Collaborators, Affiliations

The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis

Mustafa Tosur et al. J Clin Endocrinol Metab. .

Abstract

Objective: We set forth to compare ethnicities for metabolic and immunological characteristics at the clinical diagnosis of type 1 diabetes (T1D) and assess the effect of ethnicity on beta-cell functional loss within 3 years after clinical diagnosis.

Research methods and design: We studied participants in TrialNet New Onset Intervention Trials (n = 624, median age = 14.4 years, 58% male, 8.7% Hispanic) and followed them prospectively for 3 years. Mixed meal tolerance tests (MMTT) were performed within 6 months following clinical diagnosis and repeated semiannually. Unless otherwise indicated, analyses were adjusted for age, sex, BMI Z-score, and diabetes duration.

Results: At T1D clinical diagnosis, Hispanics, compared with non-Hispanic whites (NHW), had a higher frequency of diabetic ketoacidosis (DKA) (44.7% vs 25.3%, OR = 2.36, P = 0.01), lower fasting glucose (97 vs 109 mg/dL, P = 0.02) and higher fasting C-peptide (1.23 vs 0.94 ng/mL, P = 0.02) on the first MMTT, and higher frequency of ZnT8 autoantibody positivity (n = 201, 94.1% vs 64%, OR = 7.98, P = 0.05). After exclusion of participants in experimental arms of positive clinical trials, C-peptide area under the curve (AUC) trajectories during the first 3 years after clinical diagnosis were not significantly different between Hispanics and NHW after adjusting for age, sex, BMI-z score, and DKA (n = 413, P = 0.14).

Conclusion: Despite differences in the metabolic and immunological characteristics at clinical diagnosis of T1D between Hispanics and NHW, C-peptide trajectories did not differ significantly in the first 3 years following clinical diagnosis after adjustment for body mass index and other confounders. These findings may inform the design of observational studies and intervention trials in T1D.

Keywords: C-peptide; Hispanics; beta-cell function; ethnic minorities; ethnicity; type 1 diabetes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
C-peptide trajectories in the first 3 years following clinical diagnosis of T1D by race/ethnicity groups after adjustment for age, sex, BMI-z score, and DKA (n = 413). Abbreviations: AUC, area under the curve; NH, non-Hispanic.
See this image and copyright information in PMC

Comment in

References

    1. Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66(2):241-255. - PMC - PubMed
    1. Tosur M, Geyer SM, Rodriguez H, Libman I, Baidal DA, Redondo MJ; Type 1 Diabetes TrialNet Study Group . Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk. Diabetologia. 2018;61(9):2043-2053. - PMC - PubMed
    1. Gandhi K, Tosur M, Schaub R, Haymond MW, Redondo MJ. Racial and ethnic differences among children with new-onset autoimmune Type 1 diabetes. Diabet Med. 2017;34(10):1435-1439. - PubMed
    1. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group . Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 2014;63(2):739-748. - PMC - PubMed
    1. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med. 1998;128(7):517-523. - PubMed

Publication types